The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ridron     (1-hydroxy-1-phosphono-2- pyridin-3-yl...

Synonyms: Benet, Risedronate, CHEMBL923, Actonel 150, PubChem14002, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Risedronate sodium


Psychiatry related information on Risedronate sodium


High impact information on Risedronate sodium


Chemical compound and disease context of Risedronate sodium


Biological context of Risedronate sodium


Anatomical context of Risedronate sodium

  • Myeloma cells or monocytes pulsed with risedronate and then washed rendered these target cells sensitive to lysis by a Vgamma2Vdelta2 T-cell clone or cell line [19].
  • In contrast to risedronate, NE10790 inhibited bone resorption in vitro without markedly affecting osteoclast number or the F-actin "ring" structure in polarized osteoclasts [20].
  • The mean differences in BMD between the 5-mg risedronate and the placebo groups were 3.8 +/- 0.8% at the lumbar spine (P < 0.001), 4.1 +/- 1.0% at the femoral neck (P < 0.001), and 4.6 +/- 0.8% at the femoral trochanter (P < 0.001) [21].
  • The study showed that risedronate preserved trabecular architecture in the vertebra of OVX minipigs, and that bone strength is tightly coupled to bone mass and architecture [22].
  • CONCLUSIONS: Long-term treatment with risedronate affects the homogeneity and degree of mineralization without inducing hypermineralization of the bone matrix [18].

Associations of Risedronate sodium with other chemical compounds


Gene context of Risedronate sodium


Analytical, diagnostic and therapeutic context of Risedronate sodium


  1. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., Guyatt, G. Endocr. Rev. (2002) [Pubmed]
  2. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Lanza, F.L., Hunt, R.H., Thomson, A.B., Provenza, J.M., Blank, M.A. Gastroenterology (2000) [Pubmed]
  3. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Sasaki, A., Boyce, B.F., Story, B., Wright, K.R., Chapman, M., Boyce, R., Mundy, G.R., Yoneda, T. Cancer Res. (1995) [Pubmed]
  4. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. Delmas, P.D., Li, Z., Cooper, C. J. Bone Miner. Res. (2004) [Pubmed]
  5. Effects of risedronate on bone density in anorexia nervosa. Miller, K.K., Grieco, K.A., Mulder, J., Grinspoon, S., Mickley, D., Yehezkel, R., Herzog, D.B., Klibanski, A. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  6. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. McClung, M.R., Geusens, P., Miller, P.D., Zippel, H., Bensen, W.G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P.J., Reginster, J.Y. N. Engl. J. Med. (2001) [Pubmed]
  7. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., Rosen, C. Endocr. Rev. (2002) [Pubmed]
  8. Treatment of postmenopausal osteoporosis. Delmas, P.D. Lancet (2002) [Pubmed]
  9. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Kavanagh, K.L., Guo, K., Dunford, J.E., Wu, X., Knapp, S., Ebetino, F.H., Rogers, M.J., Russell, R.G., Oppermann, U. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  10. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Sato, Y., Iwamoto, J., Kanoko, T., Satoh, K. Arch. Intern. Med. (2005) [Pubmed]
  11. Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo. Wakchoure, S., Merrell, M.A., Aldrich, W., Millender-Swain, T., Harris, K.W., Triozzi, P., Selander, K.S. Clin. Cancer Res. (2006) [Pubmed]
  12. Ibandronate. Dooley, M., Balfour, J.A. Drugs (1999) [Pubmed]
  13. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Fisher, J.E., Rodan, G.A., Reszka, A.A. Endocrinology (2000) [Pubmed]
  14. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. Rendina, D., Mossetti, G., Viceconti, R., Sorrentino, M., Nunziata, V. Calcif. Tissue Int. (2004) [Pubmed]
  15. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. Delmas, P.D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., Bremond, A. J. Clin. Oncol. (1997) [Pubmed]
  16. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F.H., Delmas, P.D., Clezardin, P. Cancer Res. (1997) [Pubmed]
  17. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. Reszka, A.A., Halasy-Nagy, J.M., Masarachia, P.J., Rodan, G.A. J. Biol. Chem. (1999) [Pubmed]
  18. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. Zoehrer, R., Roschger, P., Paschalis, E.P., Hofstaetter, J.G., Durchschlag, E., Fratzl, P., Phipps, R., Klaushofer, K. J. Bone Miner. Res. (2006) [Pubmed]
  19. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Das, H., Wang, L., Kamath, A., Bukowski, J.F. Blood (2001) [Pubmed]
  20. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. Coxon, F.P., Helfrich, M.H., Larijani, B., Muzylak, M., Dunford, J.E., Marshall, D., McKinnon, A.D., Nesbitt, S.A., Horton, M.A., Seabra, M.C., Ebetino, F.H., Rogers, M.J. J. Biol. Chem. (2001) [Pubmed]
  21. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M., Zizic, T.M., Wallach, S., Sewell, K.L., Lukert, B.P., Axelrod, D.W., Chines, A.A. Arthritis Rheum. (1999) [Pubmed]
  22. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. Borah, B., Dufresne, T.E., Chmielewski, P.A., Gross, G.J., Prenger, M.C., Phipps, R.J. J. Bone Miner. Res. (2002) [Pubmed]
  23. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. Montalvetti, A., Fernandez, A., Sanders, J.M., Ghosh, S., Van Brussel, E., Oldfield, E., Docampo, R. J. Biol. Chem. (2003) [Pubmed]
  24. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. Qi, H., Li, M., Wronski, T.J. J. Bone Miner. Res. (1995) [Pubmed]
  25. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Sato, Y., Kanoko, T., Satoh, K., Iwamoto, J. Arch. Intern. Med. (2005) [Pubmed]
  26. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Reid, D.M., Hughes, R.A., Laan, R.F., Sacco-Gibson, N.A., Wenderoth, D.H., Adami, S., Eusebio, R.A., Devogelaer, J.P. J. Bone Miner. Res. (2000) [Pubmed]
  27. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., Saito, N., Hiraoka, B.Y., Kobayashi, Y., Takaoka, K., Ozawa, H., Miyazawa, H., Takahashi, N. Endocrinology (2003) [Pubmed]
  28. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. Yao, W., Balooch, G., Balooch, M., Jiang, Y., Nalla, R.K., Kinney, J., Wronski, T.J., Lane, N.E. Bone (2006) [Pubmed]
  29. -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Corral-Gudino, L., del Pino-Montes, J., García-Aparicio, J., Corral, E., Montilla, C.A., González-Sarmiento, R. Bone (2006) [Pubmed]
  30. Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. Makowski, G.S., Ramsby, M.L. Clin. Chim. Acta (2005) [Pubmed]
  31. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Fujita, H., Utsumi, T., Muranaka, S., Ogino, T., Yano, H., Akiyama, J., Yasuda, T., Utsumi, K. Biochem. Pharmacol. (2005) [Pubmed]
  32. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Van Staa, T.P., Laan, R.F., Barton, I.P., Cohen, S., Reid, D.M., Cooper, C. Arthritis Rheum. (2003) [Pubmed]
  33. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Miller, P.D., Roux, C., Boonen, S., Barton, I.P., Dunlap, L.E., Burgio, D.E. J. Bone Miner. Res. (2005) [Pubmed]
WikiGenes - Universities